Clinical Trials Directory

Trials / Completed

CompletedNCT01256697

The Effect of Oral Administration of 9-cis Rich Powder of the Alga Dunaliella Bardawil on Visual Functions im Patients With Retinitis Pigmentosa

The Effect of Oral Administration of 9-cis Rich Powder of the Alga Dunaliella

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
34 (actual)
Sponsor
Sheba Medical Center · Other Government
Sex
Female
Age
18 Years
Healthy volunteers
Not accepted

Summary

Retinitis pigmentosa is a genetically determined disease consisting of progressive centripetal retinal degeneration starting in the rods outer segments. Its prevalence is 1:4000 people and is the fourth most common blinding disease in Israel in 2004 \[7% of all blindness\]. The investigators tried to treat a non-progressive form of the disease \[Fundus Albipunctatus\] by oral therapy of the food supplement made from alga Dunaliella bardawil composed of approximately 50% 9-cis β-carotene. The alga Dunaliella bardawil accumulates high concentration of β -carotene when grown under appropriate conditions. The β -carotene of the alga is composed of approximately 50% of all-trans - β carotene and 50% 9-cis β -carotene. The 9-cis β -carotene has shown to be a precursor of 9-cis retinoic acid both in-vitro in human intestinal mucosa and in-vivo in a ferret, perfuse with 9-cis b-carotene. The night vision, as measured objectively by electroretinography (ERG) more than doubled in six patients tested. The visual field was also improved significantly.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTAlga Dunaliella Bardawil9-cis Rich Powder
DIETARY_SUPPLEMENTAlga Dunaliella Bardawill9-cis Rich Powder
OTHERSugar pillSugar pill

Timeline

Start date
2008-08-01
Primary completion
2009-04-01
Completion
2011-01-01
First posted
2010-12-08
Last updated
2013-12-20

Locations

1 site across 1 country: Israel

Source: ClinicalTrials.gov record NCT01256697. Inclusion in this directory is not an endorsement.